Poppi Goes Multi-Functional, Vitamin D Safety Signal Hits

PepsiCo expands Poppi into energy and relaxation, new vitamin D research flags a form-specific risk, Edonia raises €15m for microalgae protein, and longevity reprogramming reaches human trials.

Show Notes

PepsiCo is turning Poppi into a full functional platform with Lift and Chill lines — and a new vitamin D safety signal is putting formulation teams on alert. Two stories supplement and functional food brands cannot afford to miss.

In this episode:

• New research warns that a widely used molecular form of vitamin D may carry an unexpected negative effect, creating a formulation credibility moment for supplement brands whose EFSA-authorised claims have never required form transparency.
• PepsiCo is launching two new Poppi lines — Lift targeting energy and Chill targeting relaxation — transforming the prebiotic gut health brand into a multi-functional beverage platform and bringing it into direct competition with specialist cognitive and mood drink brands.
• French startup Edonia, backed by EIT Food, has raised €15 million to scale a whole-food microalgae protein ingredient, positioning it as a minimally processed alternative to the ultra-processed plant-based meat formats that have lost consumer trust.
• The first human trial of cellular reprogramming as a longevity intervention has produced encouraging early results, moving the approach — previously associated with Silicon Valley billionaires like Bryan Johnson — closer to clinical legitimacy.

The Health Marketing Daily is a concise briefing for marketers and founders in supplements, functional food and consumer health, hosted by Marco & Klara. New episode every day.

Enjoying the show? A quick rating or review on Apple Podcasts or Spotify helps other marketers find us.

Also from Marco & Klara: The FMCG Marketing Daily · The Digital Commerce Daily

What is The Health Marketing Daily?

The daily briefing for professionals in health, nutrition, and wellness marketing. Every episode covers an ingredient of the day, the latest science and regulatory updates from EFSA and beyond, and the brand and market moves shaping the nutraceutical industry. Hosted by Klara and Marco — evidence-based, no hype, no bro-science. Built for formulators, brand managers, regulatory affairs teams, and anyone building in the health and nutrition space.

Marco: There's a lot to dig into today.
Klara: We're looking at new research that puts a question mark over one of the world's most popular supplements — vitamin D.
Marco: Then PepsiCo is pushing its Poppi brand into multi-functional territory, and a French startup just raised €15 million to bring microalgae protein to scale.
Klara: And the first human trial on longevity reprogramming is in. Let's go.

Marco: Scientists are warning that a popular form of vitamin D supplement may come with an unexpected downside — and that's a serious issue for one of Europe's biggest supplement categories.

Marco: Vitamin D is already under intense scrutiny. Recent research linked high-dose supplementation to pancreatic cancer risk. That story hadn't fully settled before this new finding arrived.

Marco: The core issue here is that not all vitamin D supplements are the same. There are different molecular forms — different versions of the molecule — and new research suggests that one widely used form may carry a negative effect that researchers didn't previously expect. We don't yet have the full published detail, but the signal is real enough to put formulation teams on alert.

Klara: This is where I'd slow everyone down. A safety signal isn't the same as a proven harm. We need to know the study design, the doses used, and whether the effect was seen in humans or just in cell or animal models. Those distinctions matter enormously when you're deciding whether to reformulate or issue consumer communications.

Marco: That's fair, but from a commercial perspective, brands can't afford to wait for perfect certainty. Millions of European consumers take vitamin D daily — often without any professional guidance. If a journalist runs this story in a mainstream outlet, your product is in the frame whether your specific form is implicated or not.

Klara: And that's precisely why form transparency matters so much. EFSA-authorised health claims for vitamin D — things like immune function and bone health — don't distinguish between forms. Brands have never had to explain the difference. Now they might have to.

Marco: Exactly the kind of formulation credibility moment that separates the serious players from the label stackers.

Marco: Now let's move to our next story.

Klara: PepsiCo is turning Poppi from a gut health drink into a full functional beverage platform — and that move deserves close attention.

Klara: Poppi built its identity around gut health, specifically the prebiotic angle. PepsiCo acquired the brand earlier this year, and many expected a slow, cautious integration. That's not what's happening.

Klara: PepsiCo is now launching two new Poppi lines. One is called Lift — targeting energy. The other is Chill — targeting relaxation. Both take the brand into completely different functional territories, far from the original gut health story.

Klara: From a scientific standpoint, this is where things get complicated fast. Gut health has a reasonably clear ingredient story — prebiotics, fibre, fermentation. Energy and relaxation claims are a different regulatory environment entirely. In Europe, EFSA — the EU's food safety authority — has a very short list of approved health claims for ingredients used in mood and stress products. Ashwagandha, for example, still has no authorised claim in the EU. Brands have to be extremely careful about what they say on pack.

Marco: The regulatory nuance is real, but this story is primarily about distribution leverage. PepsiCo can put Poppi into petrol stations, supermarkets, and convenience chains across multiple markets simultaneously. That's infrastructure no specialist wellness brand can match.

Klara: Which is exactly why specialist brands shouldn't try to compete on reach. Compete on depth instead. Transparent ingredient sourcing, published clinical evidence, clear dosing — these are things a mass platform built for scale tends to flatten out.

Marco: The shelf space battle may be unwinnable. The credibility battle absolutely isn't.

Klara: For European functional drink and supplement brands, this is the moment to double down on what Big Food structurally cannot do.

Marco: Next story — let's keep moving.

Marco: A French startup just raised serious money to bring microalgae protein into mainstream food and supplement markets — and it's worth pausing on what that signals.

Marco: Plant-based protein has had a rough few years. The meat-alternative boom peaked, sales plateaued, and consumers started pushing back on ultra-processed ingredients. The category needed a reset. Microalgae — microscopic aquatic organisms that produce protein naturally — represents a genuinely different direction. Not a meat mimic. A whole food.

Marco: Edonia, a French startup backed by EIT Food — the EU's agri-food innovation network — has secured €15 million to scale its microalgae protein ingredient. The positioning is deliberate: whole-food, minimally processed, nutrient-dense. That's a direct response to everything consumers rejected about first-generation plant protein.

Klara: The science here is promising but still maturing. Microalgae like spirulina and chlorella have an established safety track record and some EFSA-authorised claims. But Edonia appears to be working with its own specific strain, which means the regulatory pathway could be more complex. Novel food authorisation in the EU — the process for approving ingredients that don't have a long history of use in Europe — takes time and rigorous safety evidence. I'd want to see their dossier before getting too excited about supplement applications specifically.

Marco: That's the right caution, but the positioning window is open right now. Brands that start building microalgae into their ingredient narrative — even at an early stage — will own the story when the ingredient scales. First-mover credibility in emerging ingredient categories has enormous commercial value.

Klara: As long as the marketing stays ahead of the evidence rather than ahead of the science. Those are very different things.

Marco: On that note — let's get to our final story for today.

Klara: Silicon Valley's obsession with living forever has just produced its first real human trial data on cellular reprogramming — and the results are encouraging.

Klara: Cellular reprogramming is the idea that you can reset the biological age of cells — essentially turning back the clock at a molecular level. Until now, this has been the territory of billionaires like Bryan Johnson, who spend extraordinary sums testing interventions on themselves. It's never had serious clinical validation in humans.

Klara: That's changed. Early results from the first human trial of cellular reprogramming as a longevity intervention have come back positive, according to Business Insider. The detail is still limited — we don't yet have a full peer-reviewed paper — but the signal is significant enough to shift how the longevity category gets discussed.

Klara: From a scientific standpoint, I want to be precise about what this is and isn't. One encouraging early trial does not mean the science is settled. Longevity research is notoriously difficult — endpoints take decades, and early signals frequently don't hold. But this is the first meaningful step toward clinical legitimacy for a field that has largely operated on theory and very wealthy self-experimentation.

Marco: Commercially, this is enormous for the longevity category broadly — including supplements. Consumer interest in longevity science is already high across European markets. Data like this will push it higher. The problem is that most longevity supplement brands are going to try to surf that wave with ingredients that have nothing to do with cellular reprogramming. Generic antioxidant blends or basic NAD+ products will look threadbare next to a category now anchored by human trial evidence.

Klara: That's the tension I'd flag. Riding category excitement is legitimate marketing. Implying your supplement does what cellular reprogramming does — that's where European brands run straight into EC 1924/2006, and EFSA will not be kind.

Marco: The brands worth watching are those who use this moment to be honest about what their products actually do — and position themselves as the credible, accessible end of a longevity spectrum that now has a serious scientific anchor at the top.

Marco: The biggest commercial lesson today is simple — consumers want more from every product, whether that's vitamin D, a soft drink, or a protein source, and brands that deliver multiple credible benefits will win the shelf.
Klara: But credibility is the operative word — every claim still needs the evidence to back it up.